New strategies in mCRPC focus on sequencing, genomics and earlier use of targeted therapies to improve outcomes for patients.
Weill Cornell Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners
Latest from Weill Cornell Sandra & Edward Meyer Cancer Center
Illuccix is now FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Advertisement
Advertisement
Trending on CURE
1
Why Cancer Survivorship Can Be the Hardest Part, Psychologist Says
2
Experimental Treatment Shrinks Tumors in Aggressive Adenoid Cystic Carcinoma
3
5-Year Data Support Personalized Vaccine in High-Risk Melanoma
4
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
5